Back to Search
Start Over
A comparative study of the bispecific monoclonal antibody, blinatumomab expression in CHO cells and E. coli.
- Source :
-
Preparative Biochemistry & Biotechnology . 2018, Vol. 48 Issue 10, p961-967. 7p. 7 Diagrams, 1 Chart, 4 Graphs. - Publication Year :
- 2018
-
Abstract
- The "bispecifics" market improved over the past decade due to the development of many technological platforms including bispecific T cell engagers (BiTEs). The approval of blinatumomab, the most advanced bispecific T-cell engager (BiTE) in clinical trials, can be a significant milestone in the development of bispecific antibodies. Both Chinese hamster ovary (CHO) cells and E. coli strain are considered as the most widely used hosts for the large-scale production of therapeutic monoclonal antibodies. Since both of the economic and qualitative aspects of protein production are important in industry, selection of a suitable protein expression system is very critical. The BsAb gene was cloned into the expression vectors FC550A-1, pcDNA3.1 (+), and PET22b and 6 × His-tagged BsAb then purified on a Ni-NTA chromatography column. Both SDS-PAGE and Western blotting analysis of the purified protein demonstrated that blinatumomab was successfully expressed as a 55 kDa in both expression systems. The antigen-binding properties of blinatumomab were compared in the mammalian system versus Escherichia coli. The results showed that the purified antibody from a mammalian expression system has better binding activity than the one from E. coli host. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10826068
- Volume :
- 48
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- Preparative Biochemistry & Biotechnology
- Publication Type :
- Academic Journal
- Accession number :
- 134310056
- Full Text :
- https://doi.org/10.1080/10826068.2018.1525562